LivaNova PLC (LIVN)

NasdaqGS · Medical Devices

79.53
-1.95 (-2.39%)
Updated Aug 18, 4:17 PM ET
AI Rating
Buy
Overall Score
68
Trend
72
Momentum
75
Risk
50

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Feb 19, 2026 120 sessions Aug 14, 2026

AI Analysis

LivaNova PLC is trading at $79.53, down 2.39% on the session. The 50 day average sits at $79.64 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 55.9, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $78.07 with resistance near $83.98, so that band frames the current range. Average daily movement is roughly $2.92, or about 3.7% of the share price, which is what any stop placement has to allow for. The overall health score of 68 out of 100 combines a trend score of 72, momentum of 75 and a risk score of 50.

Technical indicators

RSI (14)
55.9
strong
MACD
0.154
bullish crossover
SMA 20
80.06
SMA 50
79.64
SMA 200
--
unknown
ATR (14)
2.92
avg daily range
Support
78.07
Resistance
83.98
Volume vs 20d
0.76x
below average
Volatility
44.2%
annualised
1 month
-0.92%
3 months
+17.31%

About LivaNova PLC

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.